

April 13, 2020

To,
Mr. Piyush Tanna
Chief Manager
Surveillance
National Stock Exchange of India
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (East), Mumbai 400 051

NSE SYMBOL: AARTIDRUGS

Subject :- Movement in Price

Reference: NSE/CM/Surveillance/9266 dated April 9, 2020

Dear Sir,

With reference to your letter under Ref. No.: NSE/CM/Surveillance/9266 dated April 9, 2020 received via e-mail, we clarify as under:

Company has made all the necessary disclosures pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015 and has not withheld any material information/ event that in our opinion would have a bearing on the price/ volume behaviour of the script.

Therefore, the significant movement in share price of the Company is purely market driven. The management of the Company is no way connected in any such increase in price of the script.

You are requested to take the same on records.

Thanking you,

Yours Faithfully,
FOR AARTI DRUGS LIMITED

SD/-

RUSHIKESH DEOLE
COMPANY SECRETARY
ICSI M. NO. A54527

Note:- In line with mail received from NSE regarding Guidelines for submission on NEAPS Portal in the wake of CoVID19 virus dated March 24, 2020 we have made the submission of these documents without signature (i.e. SD/- mode) as printing and scanning facility is not available. you are request to accept this submission.